Johnson & Johnson: Valuation Premium Justified (NYSE:JNJ)

Core Insights - Johnson & Johnson's revenue and earnings growth are expected to accelerate due to the successful ramp-up of TREMFYA, which is replacing STELARA after its loss of exclusivity [1] Group 1: Company Performance - The growth of Johnson & Johnson is anticipated to benefit from the transition to TREMFYA, indicating a positive outlook for future revenue streams [1]